Literature DB >> 15794399

Cost of multiple sclerosis by level of disability: a review of literature.

M B Patwardhan1, D B Matchar, G P Samsa, D C McCrory, R G Williams, T T Li.   

Abstract

We performed a review of the economic literature to identify what is known about the relationship between Expanded Disability Status Scale (EDSS) categories and cost of multiple sclerosis (MS). We sought cohort studies of patients with multiple sclerosis that described the costs attributed to each EDSS score and utilized specific inclusion criteria for the selection of 10 studies. We found that both direct and indirect costs rise continuously with increasing EDSS category, and this rise is qualitatively exponential. The rise in indirect costs appears at lower EDSS scores. The cost of a relapse occurring in any given EDSS category exceeds that associated with that particular EDSS category. Few studies comprehensively assessed the entire spectrum of the costs, and much of the literature is based on EDSS categories in coarse groupings. In spite of several variations between studies, one important conclusion that we can draw is that rise in cost is positively correlated to scores on the EDSS categories, and therefore agents with a capacity to prevent or arrest the rate of MS progression may affect the overall cost of MS.

Entities:  

Mesh:

Year:  2005        PMID: 15794399     DOI: 10.1191/1352458505ms1137oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  30 in total

Review 1.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

2.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.

Authors:  Scott D Newsome; Bernd C Kieseier; Shifang Liu; Xiaojun You; Elizabeth Kinter; Serena Hung; Bjoern Sperling
Journal:  Ther Adv Neurol Disord       Date:  2016-11-16       Impact factor: 6.570

4.  Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.

Authors:  Oliver Neuhaus; Olaf Stüve; Scott S Zamvil; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Burden of a multiple sclerosis relapse: the patient's perspective.

Authors:  Merrikay Oleen-Burkey; Jane Castelli-Haley; Maureen J Lage; Kenneth P Johnson
Journal:  Patient       Date:  2012       Impact factor: 3.883

6.  Multiple sclerosis and rehabilitation: an overview of the different rehabilitation settings.

Authors:  Andrea Tacchino; Giampaolo Brichetto; Paola Zaratin; Mario Alberto Battaglia; Michela Ponzio
Journal:  Neurol Sci       Date:  2017-09-15       Impact factor: 3.307

7.  Multiple sclerosis: relapses, resource use, and costs.

Authors:  A J Hawton; C Green
Journal:  Eur J Health Econ       Date:  2015-10-05

8.  Change in perceived health insurance coverage among people with multiple sclerosis.

Authors:  Alyssa Pozniak; Louise Hadden; William Rhodes; Sarah Minden
Journal:  Int J MS Care       Date:  2014

9.  Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs.

Authors:  Michela Ponzio; Simone Gerzeli; Giampaolo Brichetto; Daiana Bezzini; Gian Luigi Mancardi; Paola Zaratin; Mario Alberto Battaglia
Journal:  Neurol Sci       Date:  2014-08-11       Impact factor: 3.307

10.  Cortical atrophy is relevant in multiple sclerosis at clinical onset.

Authors:  Massimiliano Calabrese; Matteo Atzori; Valentina Bernardi; Aldo Morra; Chiara Romualdi; Luciano Rinaldi; Matthew J M McAuliffe; Luigi Barachino; Paola Perini; Bruce Fischl; Leontino Battistin; Paolo Gallo
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.